[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-333083-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-333083-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","brca-12-mutations-and-risk-of-uterine-cancer-a-systematic-review-and-meta-analysis","BRCA 1/2 mutations and risk of uterine cancer - a systematic review and meta-analysis","","Study purpose centers on whether BRCA1/2 mutations are associated with uterine cancer incidence. Methods include a systematic search of PubMed, Scopus, and Google Scholar through August 2023, reviewing 23 cohorts and cross-sectional studies. Results synthesize 21 cohort studies and 2 cross-sectional studies; meta-analysis estimates BRCA1/2 prevalence in uterine cancer patients at 0.02 (95% CI [0.01, 0.03], P\u003C0.01, I2=94.82%). Conclusions indicate about 2% prevalence and suggest BRCA1/2 mutation carriers may show greater awareness of uterine malignancies.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/brca-12-mutations-and-risk-of-uterine-cancer-a-systematic-review-and-meta-analysis/333083/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/brca-12-mutations-and-risk-of-uterine-cancer-a-systematic-review-and-meta-analysis/333083.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s purpose regarding BRCA1/2 mutations and uterine cancer?","Question",{"text":63,"@type":64},"The study investigates the association between BRCA1/2 mutation and uterine cancer incidence.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the literature search conducted?",{"text":68,"@type":64},"The authors searched PubMed, Scopus, and Google Scholar up to August 2023 and screened 23 cohorts and cross-sectional studies.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the meta-analysis find about BRCA1/2 prevalence in uterine cancer patients?",{"text":72,"@type":64},"The meta-analysis estimated a prevalence of 0.02 (2%) BRCA1/2 in uterine cancer patients (95% CI [0.01, 0.03], P\u003C0.01; I2=94.82%).",{"name":74,"@type":61,"acceptedAnswer":75},"What conclusion did the authors draw from the findings?",{"text":76,"@type":64},"They report a ~2% prevalence of BRCA1/2 mutation among uterine cancer patients and suggest mutation carriers might be more conscious of uterine malignancies.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},333083,1790012907,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Zakerinasab etal. BMC Genomic Data (2024) 25:13  \n[https://doi.org/10.1186/s12863-024-01189-y](https://doi.org/10.1186/s12863-024-01189-y)  \nBMC Genomic Data  \nRESEARCH Open Access  \nBRCA 1/2 mutations and risk of uterine cancer:   a systematic review and meta-analysis  \nFaezeh Zakerinasab 1, Qumars Behfar2, Reza Parsaee3, Reza Hossein Zadeh4, Elaheh Foroughi5, Amirhesam Amirbeik6 and Ghazalehsadat Ahmadi 1*  \nAbstract  \nPurpose In this study, we aim to investigate the association between BRCA1/2 mutation and uterine cancer incidence.  \nMaterial and method We systematically searched three databases including PubMed, Scopus, and Google Scholar up to August 2023; and reviewed 23 cohorts and cross-sectional studies to explore the association between BRCA1/2 mutations and uterine cancer incidence.  \nResults This systematic review comprised a total of 21 cohort studies and 2 cross-sectional studies after the screening process. According to meta-analysis the prevalence of the BRCA1/2 gene in patients with uterine cancer was 0.02 (95%CI = [0 . 01,0 . 03], P \u003C 0. 01, I2 = 94 . 82%)  \nConclusions Our meta-analysis investigates a 2% prevalence of BRCA1/2 mutation in patients with uterine cancer. Patients with BRCA1/2 mutations might be more conscious of uterine malignancies.  \nKeywords BRCA1, BRCA2, Mutation, Uterine cancer, Endometrial  \nBackground  \nUterine cancer risk in BRCA1/2m women and its significance in the BRCA mutated condition are still beyond controversy. The similarities between serous ovarian and uterine cancers, especially serous carcinomas, have prompted researchers to look for shared pathogenetic  \n*Correspondence: Ghazalehsadat Ahmadi [Ghazale_6053@yahoo.com](Ghazale_6053@yahoo.com)  \n1Mashhad University of Medical Sciences, Mashhad, Iran  \n2Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany  \n3Master Student in Molecular Genetics, Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran  \n4Student’s Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran  \n5School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 6Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran  \ntraits as well as hereditary factors. Even though the particular gene sequence implicated is mostly unclear, 10% of the cases of endometrial cancer are found to have positive family histories, suggesting a genetic tendency [1]. BRCA1 is located in chromosome 17q21, whereas BRCA2 is located in chromosome 13q12, which are both autosomal dominant tumor suppressor genes involved in DNA damage repair prior to cell replication [2, 3]. BRCA1 and BRCA2 mutation carriers’ risk of developing uterine cancer is still unknown due to inconsistent results from various studies that may have been impacted by past tamoxifen treatment. However, the majority of research has indicated an approximately two-fold increase in risk compared to the general population [4]. A higher risk of endometrial cancer, and especially uterine serous carcinoma in BRCA1m women, was verified by some writers [5–7], but not by others [8, 9]. 11,847 BRCA1 variant carriers participated in global cohort  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted us","cbCaihSSRm6oZWNt","https://ap.wps.com/l/cbCaihSSRm6oZWNt","pdf",2185142,"English","# Abstract\n## Purpose\n## Material and method\n## Results\n## Conclusions\n# Background","[{\"question\":\"What is the study’s purpose regarding BRCA1/2 mutations and uterine cancer?\",\"answer\":\"The study investigates the association between BRCA1/2 mutation and uterine cancer incidence.\"},{\"question\":\"How was the literature search conducted?\",\"answer\":\"The authors searched PubMed, Scopus, and Google Scholar up to August 2023 and screened 23 cohorts and cross-sectional studies.\"},{\"question\":\"What did the meta-analysis find about BRCA1/2 prevalence in uterine cancer patients?\",\"answer\":\"The meta-analysis estimated a prevalence of 0.02 (2%) BRCA1/2 in uterine cancer patients (95% CI [0.01, 0.03], P\\u003c0.01; I2=94.82%).\"},{\"question\":\"What conclusion did the authors draw from the findings?\",\"answer\":\"They report a ~2% prevalence of BRCA1/2 mutation among uterine cancer patients and suggest mutation carriers might be more conscious of uterine malignancies.\"}]","BRCA 1/2 mutations and risk of uterine cancer - a systematic review and meta-analysis | PDF",1790000793,28]